Search Page

1

Cite

Share

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Camilleri M, et al. Among authors: dukes ge. Lancet. 2000 Mar 25;355(9209):1035-40. doi: 10.1016/S0140-6736(00)02033-X. Lancet. 2000. PMID: 10744088 Clinical Trial.

Cite

Share

2

Cite

Share

Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health.

Grudell AB, Camilleri M, Jensen KL, Foxx-Orenstein AE, Burton DD, Ryks MD, Baxter KL, Cox DS, Dukes GE, Kelleher DL, Zinsmeister AR. Grudell AB, et al. Among authors: dukes ge. Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1114-9. doi: 10.1152/ajpgi.00051.2008. Epub 2008 Mar 27. Am J Physiol Gastrointest Liver Physiol. 2008. PMID: 18372395 Clinical Trial.

Cite

Share

3

Cite

Share

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.

Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. Hegade VS, et al. Among authors: dukes ge. Lancet. 2017 Mar 18;389(10074):1114-1123. doi: 10.1016/S0140-6736(17)30319-7. Epub 2017 Feb 8. Lancet. 2017. PMID: 28187915 Clinical Trial.

Cite

Share

4

Cite

Share

A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.

Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW. Talley NJ, et al. Aliment Pharmacol Ther. 2001 Apr;15(4):525-37. doi: 10.1046/j.1365-2036.2001.00941.x. Aliment Pharmacol Ther. 2001. PMID: 11284782 Clinical Trial.

Cite

Share

5

Cite

Share

Distinct neurophysiological profiles in irritable bowel syndrome.

Arebi N, Bullas DC, Dukes GE, Gurmany S, Hicks KJ, Kamm MA, Hobson AR. Arebi N, et al. Among authors: dukes ge. Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G1086-93. doi: 10.1152/ajpgi.00553.2010. Epub 2011 Feb 24. Am J Physiol Gastrointest Liver Physiol. 2011. PMID: 21350185

Cite

Share

6

Cite

Share

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Chey WD, et al. Among authors: dukes ge. Am J Gastroenterol. 2004 Nov;99(11):2195-203. doi: 10.1111/j.1572-0241.2004.30509.x. Am J Gastroenterol. 2004. PMID: 15555002 Clinical Trial.

Cite

Share

7

Cite

Share

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. Chang L, et al. Among authors: dukes ge. Am J Gastroenterol. 2005 Jan;100(1):115-23. doi: 10.1111/j.1572-0241.2005.40365.x. Am J Gastroenterol. 2005. PMID: 15654790 Clinical Trial.

Cite

Share

8

Cite

Share

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM. Camilleri M, et al. Among authors: dukes ge. Arch Intern Med. 2001 Jul 23;161(14):1733-40. doi: 10.1001/archinte.161.14.1733. Arch Intern Med. 2001. PMID: 11485506 Clinical Trial.

Cite

Share

9

Cite

Share

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Wolfe SG, et al. Among authors: dukes ge. Am J Gastroenterol. 2001 Mar;96(3):803-11. doi: 10.1111/j.1572-0241.2001.03626.x. Am J Gastroenterol. 2001. PMID: 11280555 Clinical Trial.

Cite

Share

10

Cite

Share

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.

Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, Kong S, Mangel AW, Northcutt AR. Camilleri M, et al. Among authors: dukes ge. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59. doi: 10.1046/j.1365-2036.1999.00610.x. Aliment Pharmacol Ther. 1999. PMID: 10468696 Clinical Trial.

Cite

Share